| 名稱 | Regorafenib |
| 描述 | Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor that inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ and is orally active. Regorafenib has antitumor and anti-angiogenic activity. |
| 細胞實驗 | Each cell line was seeded at 0.3×10^5 cells/2ml of DMEM containing 10% FBS in 35 mm tissue culture dishes. The cells were incubated for 24 h to allow attachment, and then the medium was replaced by fresh culture medium containing Regorafenib at increasing concentrations (1 μM, 2.5 μM, 5 μM, 7.5 μM and 10 μM). In these experimental conditions, the cells were allowed to grow for 72 or 96 h. Time-course experiments on Hep3B cells were performed with 7.5 μM of Regorafenib at short (15, 60, 180 min.), middle (24, 48, 72 and 96 h) or long times (up to seven days). When the cells were treated for long times the drug was replaced with a fresh one. Each experiment included a control with the equivalent concentration of DMSO (solvent control) as the one used for adding Regorafenib. Each experiment was performed in triplicate and repeated 3 times. Subsequent analyses were performed at specific Regorafenib concentrations and incubation times [2]. |
| 激酶實驗 | In vitro assays using recombinant VEGFR2 (murine aa785–aa1367), VEGFR3 (murine aa818–aa1363), PDGFR-b (aa561–aa1106), RAF-1 (aa305–aa648) and BRAFV600E (aa409–aa765) kinase domains were performed as previously described. Initial in vitro kinase inhibition profiling was performed at a fixed 1 μM compound concentration under Millipore standard conditions [10 μM adenosine-50'- triphosphate (ATP) concentration]. Inhibitory concentration of 50% (IC50) values were determined from selected responding kinases, e.g., VEGFR1 and RET. TIE2 kinase inhibition was measured with a homogeneous time-resolved fluorescence (HTRF) assay using a recombinant fusion protein of glutathione-S-transferase, the intracellular domain of TIE2 and the peptide biotin-Ahx-EPKDDAYPLYSDFG as substrate. |
| 動物實驗 | Female athymic NCr nu/nu mice, kept in accordance with Federal guidelines, were subcutaneously inoculated with 5×10^6 Colo-205 or MDAMB-231 cells or implanted with 1 mm^3 786-O tumor fragments. When tumors reached a volume of ~100 mm^3, regorafenib or vehicle control was administered orally qd×21 in the 786-O model, and qd×9 in the Colo-205 and MDA-MB231 models, respectively, at doses of 100, 30, 10, and 3 mg/kg. Paclitaxel was administered intravenously at 10 mg/kg in ethanol/Cremophor ELV/saline (12.5%/12.5%/75%) every 2 days×5. Tumor size (volume) was estimated twice weekly (l×w^2)/2, and the percentage of tumor growth inhibition (TGI) was obtained from terminal tumor weights (1-T/C100). Mice were weighed every other day starting from the first day of treatment. The general health status of the mice was monitored daily [1]. |
| 體外活性 | 方法：人肝癌細胞 Hep3B、PLC/PRF/5 和 HepG2 用 Regorafenib (0-10 μM) 處理 72 h，使用 MTT 方法檢測細胞活力。
結(jié)果：Regorafenib 濃度依賴性降低 Hep3B 細胞活力，IC50 約為 5 μM。PLC/PRF/5 細胞的敏感性與 Hep3B細胞相似。但 HepG2 細胞更敏感，IC50 約為 1 μM。[1]
方法：腫瘤細胞 NIH-3T3/VEGFR2、CHO/TIE2、HAoSMC/PDGFR-β 和 MCF-7/FGFR 用 Regorafenib (10-3000 nM) 處理 1 h，使用 Western Blot 方法檢測靶點蛋白表達水平。
結(jié)果：Regorafenib 抑制 p-VEGFR2、p-TIE2、p-PDGFR-β 和 p-FGFR。[2] |
| 體內(nèi)活性 | 方法：為檢測體內(nèi)抗腫瘤活性，將 Regorafenib (3-100 mg/kg) 口服給藥給攜帶腫瘤 Colo-205 或 MDA-MB-231 的 NCr nu/nu 小鼠，每天一次，持續(xù)九天。
結(jié)果：Regorafenib 抑制腫瘤生長。Colo-205 模型中，Regorafenib 在 10 mg/kg 的劑量下，第 14 天的 TGI 達到 75%。MDA-MB-231 模型，Regorafenib 在低至 3 mg/kg 的劑量下是高效的，導致 81% 的顯著TGI。[2]
方法：為檢測體內(nèi)抗腫瘤活性，將 Regorafenib (3-10 mg/kg) 口服給藥給攜帶腫瘤 HT-29 或 MDA-MB-231 的 NMRI nu/nu 小鼠，每天一次，持續(xù)二十七天。
結(jié)果：Regorafenib 劑量依賴性抑制 HT-29 和 MDA-MB-231 腫瘤生長。[3] |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | DMSO : 126.3 mg/mL (261.59 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 9 mg/mL (18.64 mM), Suspension.
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
H2O : < 1 mg/mL (insoluble or slightly soluble)
|
| 關(guān)鍵字 | VEGFR2 | VEGFR1 | VEGFR | Vascular endothelial growth factor receptor | tumor | SCFR | RET | Regorafenib | Raf-1 | Raf kinases | Raf | Platelet-derived growth factor receptor | PDGFR | NIH-3T3 | Kit | Inhibitor | inhibit | HUVECs | Hep3B cell | HAoSMCs | Fibroblast growth factor receptor | FGFR | cRET | Colo-205 | c-Kit | cKit | CD117 | Autophagy | Antitumorigenic | antiangiogenic | 786-O |
| 相關(guān)產(chǎn)品 | Guanidine hydrochloride | Naringin | Aceglutamide | Alginic acid | Cysteamine hydrochloride | Hemin | Hydroxychloroquine | Ferulic Acid | Sildenafil citrate | Stavudine | Tamoxifen | Paeonol |
| 相關(guān)庫 | 抑制劑庫 | 抗癌上市藥物庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | 激酶抑制劑庫 | 臨床失敗化合物庫 | EMA 上市藥物庫 | FDA 上市藥物庫 | 膜蛋白靶向化合物庫 | 疼痛相關(guān)化合物庫 | FDA 上市激酶抑制劑庫 | 抗癌藥物庫 |